Viatris, formerly Mylan, agrees to pay $264 million to resolve US antitrust claims over EpiPen
MLex Summary: Viatris, formerly Mylan, has agreed to pay $264 million to resolve indirect purchasers' claims accusing it of conspiring to delay the market entry of generic EpiPen. The company said...To view the full article, register now.
Already a subscriber? Click here to view full article